je.st
news
Home
› Lilly Discontinues Phase 3 Rheumatoid Arthritis Program For Tabalumab Based On Efficacy Results
Lilly Discontinues Phase 3 Rheumatoid Arthritis Program For Tabalumab Based On Efficacy Results
2013-02-08 09:17:08| Biotech - Topix.net
Eli Lilly and Company announced today that it will discontinue the Phase 3 rheumatoid arthritis program for tabalumab, an anti-BAFF monoclonal antibody, due to lack of efficacy.
Tags: results
based
program
phase
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||